Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Alexander Egeberg; Joseph F. Merola; Knut Schäkel; L. Puig; Patrick Mahar; Isabella Yali Wang; Imre Pávó; Christopher Schuster; Christopher Em Griffiths

doi:10.3389/fmed.2022.1092688

Abstract

1 min read

Despite the higher rate of obesity and extreme obesity in patients with prediabetes and T2D, ixekizumab was an efficacious treatment in treating patients with psoriasis.

Related publications

Article2020

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp

Corrigendum2023

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Alexander Egeberg, Joseph F. Merola, Knut Schäkel, L. Puig, Patrick Mahar, Isabella Yali Wang, Imre Pávó, Christopher Schuster, Christopher Em Griffiths

Article2025

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity

Mark Lebwohl, Jerry Bagel, Ranga Gogineni, Christopher Em Griffiths

Article2022

Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure

Christopher Em Griffiths, Melinda Gooderham, Jean‐Frédéric Colombel, Tadashi Terui, Ana P. Accioly, Gaia Gallo, Danting Zhu, Andrew Blauvelt

Article2017

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt, Kim Papp, Christopher Em Griffiths, L. Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin